Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials

Cytotherapy

Volumn 9, Issue 7, 2007, Pages 613-629

  Digiusto, D L ^a   Cooper, L J N ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gene therapy; Good manufacturing practice; Immunotherapy; T cell manufacturing

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD40 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; L SELECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OKT 3; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; CELL SELECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG TOLERABILITY; GENE TRANSFER; GLIOMA; GOOD MANUFACTURING PRACTICE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; PRIORITY JOURNAL; REVIEW; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VIREMIA; VIRUS IMMUNITY;

ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CLINICAL TRIALS AS TOPIC; CULTURE MEDIA; CYTOKINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 35349030307     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240701650320     Document Type: Review

References (132)

1. Powell Jr, DJ, Dudley, ME and Hogan, KA (2006) Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol, 177, pp. 6527-6539.
2. Kershaw, MH, Westwood, JA and Parker, LL (2006) A phase I study on adoptive immunotherapy using gene-modified T-cells for ovarian cancer. Clin Cancer Res, 12, pp. 6106-6115.
3. Zhou, J., Dudley, ME and Rosenberg, SA (2004) Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J Immunol, 173, pp. 7622-7629.
4. Hami, LS, Green, C. and Leshinsky, N. (2004) GMP production and testing of Xcellerated T-cells for the treatment of patients with CLL. Cytotherapy, 6, pp. 554-562.
5. Rapoport, AP, Stadtmauer, EA and Aqui, N. (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med, 11, pp. 1230-1237.
6. Zhou, J., Dudley, ME and Rosenberg, SA (2005) Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother, 28, pp. 53-62.
7. Dudley, ME, Wunderlich, Jr and Yang, JC (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 23, pp. 2346-2357.
8. Rosenberg, SA and Dudley, ME. (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA, 101, pp. 14639-14645.
9. Dudley, ME, Wunderlich, J. and Nishimura, MI (2001) Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother, 24, pp. 363-373.
10. Dudley, ME, Wunderlich, JR and Robbins, PF (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 298, pp. 850-854.
11. + tumor-reactive effector memory T-cells in humans after adoptive cell transfer therapy. Blood, 105, pp. 241-250.
12. Gottschalk, S., Heslop, HE and Rooney, CE. (2005) Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma, 46, pp. 1-10.
13. Perruccio, K., Tosti, A. and Burchielli, E. (2005) Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood, 106, pp. 4397-4406.
14. Cobbold, M., Khan, N. and Pourgheysali, B. (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med, 202, pp. 379-386.
15. + T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood, 103, pp. 3565-3572.
16. Rooney, CM, Smith, CA and Ng, CY (1998) Infusion of cytotoxic T-cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92, pp. 1549-1555.
17. Comoli, P., Labirio, M. and Basso, S. (2002) Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T-cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood, 99, pp. 2592-2598.
18. Walter, EA, Grenberg, PD and Gilbert, MJ (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med, 333, pp. 1038-1044.
19. Rossig, C., Bollard, CM and Calonge, MJ (2002) Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: Potential for improved immunotherapy. Blood, 99, pp. 2009-2016.
20. Rizzuto, GA and Wolchok, JD. (2005) Persistence makes perfect: The benefits of IL-2 in adoptive immunotherapy. Cytotherapy, 7, pp. 391-392.
21. Atkins, MB. (2006) Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res, 12, p. S2353.
22. + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T-cells. Proc Natl Acad Sci USA, 99, pp. 16168-16173.
23. Singh, H., Serrano, LM and Pfeiffer, T. (2007) Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. Cancer Res, 67, pp. 2872-2880.
24. Wherry, EJ, Teichgraber, V. and Becker, TC (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol, 4, pp. 225-234.
25. + T-cells confer superior antitumor immunity compared with effector memory T-cells. Proc Natl Acad Sci USA, 102, pp. 9571-9576.
26. Liu, Z. and Fan, H. (2005) Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines. Cytotherapy, 7, pp. 353-362.
27. + memory stem cells in graft-versus-host disease. Nat Med, 11, pp. 1299-1305.
28. Zhang, Y., Joe, G. and Hexner, E. (2005) Alloreactive memory T-cells are responsible for the persistence of graft-versus-host disease. J Immunol, 174, pp. 3051-3058.
29. Berger, C., Jensen, MC and Riddell, SR (2006) Abstract 866. Blood, 108
30. Cooper, LJ, Kalos, M. and Lewinsohn, DA (2000) Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol, 74, pp. 8207-8212.
31. Morgan, RA, Dudley, ME and Wunderlich, JR (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314, pp. 126-129.
32. + T-cells with helper activity as well as cytotoxic capacity. Gene Ther, 12, pp. 1686-1695.
33. Scholten, KB, Schreurs, MW and Ruizendaal, JJ (2005) Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin Immunol, 114, pp. 119-129.
34. + melanoma-reactive T-cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res, 65, pp. 1570-1576.
35. Kahlon, KS, Brown, C. and Cooper, LJ (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T-cells. Cancer Res, 64, pp. 9160-9166.
36. Jensen, MC, Cooper, LJ and Wu, AM (2003) Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy, 5, pp. 131-138.
37. Cooper, LJ, Topp, MS and Serrano, M. (2003) T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood, 101, pp. 1637-1644.
38. Ahmad, M., Rees, RC and Ali, SA. (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother, 53, pp. 844-854.
39. Willemsen, RA, Weijtens, ME and Ronteltap, C. (2000) Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther, 7, pp. 1369-1377.
40. Kuball, J., Dossett, ML and Wolfl, M. (2007) Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood, 109, pp. 2331-2338.
41. Cohen, CJ, Li, YF and El-Gamil, M. (2007) Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res, 67, pp. 3898-3903.
42. Cohen, CJ, Zhao, Y. and Zheng, Z. (2006) Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res, 66, pp. 8878-8886.
43. Cooper, LJ, Kalos, M. and DiGiusto, D. (2005) T cell genetic modification for re-directed tumor recognition. Cancer Chemother Biol Resp Modifiers, 22, pp. 293-324.
44. Jensen, MC, Popplewell, L. and DiGiusto, D. (2007) A first-in-human clinical trial of adoptive therapy using CD19-specific chimeric antigen receptor re-directed T cells for recurrent/refractory follicular lymphoma. Mol Ther, 15, p. S142.
45. Kershaw, MH, Westwood, JA and Parker, LL (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res, 12, pp. 6106-6115.
46. Park, JR, Digiusto, DL and Slovak, M. (2007) Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther, 15, pp. 825-833.
47. Lamers, CH, Sleijfer, S. and Vulto, AG (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol, 24, p. e20.
48. Lamers, CH, Langeveld, SC and Ruijven, CM Groot-van (2007) Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother
49. Walker, RE, Bechtel, CM and Natarajan, V. (2000) Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood, 96, pp. 467-474.
50. Mitsuyasu, RT, Anton, PA and Deeks, SG (2000) Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood, 96, pp. 785-793.
51. Eshhar, Z., Waks, T. and Gross, G. (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA, 90, pp. 720-724.
52. Peggs, KS and Allison, JP. (2005) Co-stimulatory pathways in lymphocyte regulation: The immunoglobulin superfamily. Br J Haematol, 130, pp. 809-824.
53. Altvater, B., Pscherer, S. and Landmejer, S. (2006) CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T-cells. Clin Exp Immunol, 144, pp. 447-457.
54. Maher, J., Brentjens, RJ and Gunset, G. (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/ CD28 receptor. Nat Biotechnol, 20, pp. 70-75.
55. Loskog, A., Giandomenico, V. and Rossig, C. (2006) Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia, 20, pp. 1819-1828.
56. Kowolik, CM, Topp, MS and Gonzalez, S. (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T-cells. Cancer Res, 66, pp. 10995-11004.
57. Imai, C., Mihara, K. and Andreansky, M. (2004) Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia, 18, pp. 676-684.
58. Westwood, JA, Smyth, MJ and Teng, MW (2005) Adoptive transfer of T-cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA, 102, pp. 19051-19056.
59. Berger, C., Flowers, ME and Warren, EH (2006) Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T-cells after allogeneic hematopoietic cell transplantation. Blood, 107, pp. 2294-2302.
60. Kornblau, SM, Aycox, PG and Stephens, C. (2007) Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Exp Hematol, 35, pp. 842-853.
61. Traversari, C., Marktel, S. and Magnani, Z. (2007) The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood, 109, pp. 4708-4715.
62. Ciceri, F., Bonini, C. and Marktel, S. (2007) Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood, 109, pp. 4698-4707.
63. Straathof, KC, Pule, MA and Yotnda, P. (2005) An inducible caspase 9 safety switch for T-cell therapy. Blood, 105, pp. 4247-4254.
64. Sato, T., Neschadim, A. and Konrad, M. (2007) Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther, 15, pp. 962-970.
65. Hacein-Bey-Abina, S., Von Kalle, C. and Schmidt, M. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, pp. 415-419.
66. Ivics, Z., Hackett, PB, Plasterk, RH and Izsvak, Z. (1997) Molecular reconstruction of sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell, 91, pp. 501-510.
67. Geurts, AM, Hackett, CS and Bell, JB (2006) Structure-based prediction of insertion-site preferences of transposons into chromosomes. Nucleic Acids Res, 34, pp. 2803-2811.
68. Frommolt, R., Rohrbach, F. and Theobald, M. (2006) Sleeping Beauty transposon system: Future trend in T-cell-based gene therapies?. Future Oncol, 2, pp. 345-349.
69. Huang, X., Wilber, AC and Bao, L. (2006) Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood, 107, pp. 483-491.
70. Hackett, PB. (2007) Integrating DNA vectors for gene therapy. Mol Ther, 15, pp. 10-12.
71. Lemarie, C., Calmels, B. and Malenfant, C. (2005) Clinical experience with the delivery of thawed and washed autologous blood cells, with an automated closed fluid management device: CytoMate. Transfusion, 45, pp. 737-742.
72. Lemarie, C., Sugaye, R. and Kaur, I. (2007) Purification of monocytes from cryopreserved mobilized apheresis products by elutriation with the Elutra device. J Immunol Methods, 318, pp. 30-36.
73. + cell engraftment, ex vivo expansion, and malignant cell depletion following immunomagnetic selection. J Hematother, 7, pp. 175-183.
74. + cell selection from frozen cord blood products using the Isolex 300i and CliniMACS CD34 selection devices. J Hematother, 7, pp. 457-461.
75. Orchard, PJ, Blazer, BR and Burger, S. (2002) Clinical-scale selection of anti-CD3/CD28-activated T-cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. Hum Gene Ther, 13, pp. 979-988.
76. Watts, MJ, Somervaille, TC and Ings, SJ (2002) Variable product purity and functional capacity after CD34 selection: A direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices. Br J Haematol, 118, pp. 117-123.
77. + cells in autologous stem cell transplantation for breast cancer. Blood, 87, pp. 1687-1691.
78. Jayasinghe, SM, Wunderlich, J. and McKee, A. (2006) Sterile and disposable fluidic subsystem suitable for clinical high speed fluorescence-activated cell sorting. Cytometry B Clin Cytom, 70, pp. 344-354.
79. Lennartz, K., Flasshove, M., Moritz, T. and Kirstein, U. (2005) Improving the biosafety of cell sorting by adaptation of a cell sorting system to a biosafety cabinet. Cytometry A, 66, pp. 119-127.
80. Oberyszyn, AS and Robertson, FM. (2001) Novel rapid method for visualization of extent and location of aerosol contamination during high-speed sorting of potentially biohazardous samples. Cytometry, 43, pp. 217-222.
81. Perfetto, SP, Ambrozak, DR, Roederer, M. and Koup, RA. (2004) Viable infectious cell sorting in a BSL-3 facility. Methods Mol Biol, 263, pp. 419-424.
82. Lennartz, K. and Flasshove, M. (2005) Improving the biosafety of cell sorting by adaptation of a cell sorting system to a biosafety cabinet. Cytometry A, 66, pp. 119-127.
83. Gentry, T., Foster, S. and Winstead, L. (2007) Simultaneous isolation of human BM hematopoietic, endothelial and mesenchymal progenitor cells by flow sorting based on aldehyde dehydrogenase activity: Implications for cell therapy. Cytotherapy, 9, pp. 259-274.
84. Nagano, M., Yamashita, T. and Hamada, H. (2007) Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood. Blood, 110, pp. 151-160.
85. Storms, RW, Green, PD and Safford, KM (2005) Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood, 106, pp. 95-102.
86. Hess, DA, Wirthlin, L. and Craft, TP (2006) Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood, 107, pp. 2162-2169.
87. Riddell, SR, Watanabe, KS and Goodrich, JM (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science, 257, pp. 238-241.
88. Cooper, LJ, Ausubel, L. and Gutierrez, M. (2006) Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy, 8, pp. 105-117.
89. Numbenjapon, T., Serrano, LM and Singh, H. (2006) Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T-cells. Leukemia, 20, pp. 1889-1892.
90. Oelke, M., Maus, MV and Didiano, D. (2003) Ex vivo induction and expansion of antigen-specific cytotoxic T-cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med, 9, pp. 619-624.
91. + T-cells. Clin Immunol, 106, pp. 16-22.
92. Thomas, AK, Maus, MV and Shalaby, WS (2002) A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol, 105, pp. 259-272.
93. Maus, MV, Thomas, AK and Leonard, DG (2002) Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol, 20, pp. 143-148.
94. Garlie, NK, LeFever, AV and Siebenlist, RE (1999) T-cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J Immunother, 22, pp. 336-345.
95. + T-cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother, 7, pp. 437-448.
96. Trickett, AE, Kwan, YL and Cameron, B. (2002) Ex vivo expansion of functional T lymphocytes from HIV-infected individuals. J Immunol Methods, 262, pp. 71-83.
97. Bernstein, WB, Cox, JH and Aronson, NE (2004) Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T-cells to HIV-infected persons. Clin Immunol, 111, pp. 262-274.
98. Laport, GG, Levine, BL and Stadtmauer, EA (2003) Adoptive transfer of costimulated T-cells induces lymphocytosis in patients with relapsed/ refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood, 102, pp. 2004-2013.
99. Porter, DL, Levine, BL and Bunin, N. (2006) A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood, 107, pp. 1325-1331.
100. Santegoets, SJ, Schreurs, MW and Masterson, AJ (2006) In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. Cancer Immunol Immunother, 55, pp. 1480-1490.
101. + cytotoxic T-cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther, 13, pp. 1027-1036.
102. + T-cells for the treatment of patients with metastatic melanoma. J Clin Oncol, 24, pp. 5060-5069.
103. Trivedi, D., Wiliams, RY and O'Reilly, RJ (2005) Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood, 105, pp. 2793-2801.
104. Peng, JC, Thomas, R. and Nielsen, LK. (2005) Generation and maturation of dendritic cells for clinical application under serum-free conditions. J Immunother, 28, pp. 599-609.
105. Elias, M., van Zanten, J. and Hospers, GA (2005) Closed system generation of dendritic cells from a single blood volume for clinical application in immunotherapy. J Clin Apher, 20, pp. 197-207.
106. Adamson, L., Palmborg, A. and Svensson, A. (2004) Development of a technology platform for large-scale clinical grade production of DC. Cytotherapy, 6, pp. 363-371.
107. Sorg, RV, Ozcan, Z. and Brefort, T. (2003) Clinical-scale generation of dendritic cells in a closed system. J Immunother, 26, pp. 374-383.
108. Thurner, B., Roder, C. and Dieckmann, D. (1999) Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods, 223, pp. 1-15.
109. Wu, JY, Ernstoff, MS and Hill, JM (2006) Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. Cytotherapy, 8, pp. 141-148.
110. Klingemann, HG and Martinson, J. (2004) Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy, 6, pp. 15-22.
111. Tam, YK, Martinson, JA and Doligosa, K. (2003) Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy, 5, pp. 259-272.
112. Robinson, KL, Ayello, J. and Hughes, R. (2002) Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation. Exp Hematol, 30, pp. 245-251.
113. Warncke, M., Dodero, A. and Dierbach, H. (2006) Murine dendritic cells generated under serum-free conditions have a mature phenotype and efficiently induce primary immune responses. J Immunol Methods, 310, pp. 1-11.
114. Sombroek, CC, Stam, AG and Masterson, AJ (2002) Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol, 168, pp. 4333-4343.
115. Upham, JW, Holt, BJ and Baron-Hay, MJ (1995) Inhalant allergen-specific T-cell reactivity is detectable in close to 100% of atopic and normal individuals: Covert responses are unmasked by serum-free medium. Clin Exp Allergy, 25, pp. 634-642.
116. Carlens, S., Gilljam, M. and Remberger, M. (2000) Ex vivo T lymphocyte expansion for retroviral transduction: Influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution. Exp Hematol, 28, pp. 1137-1146.
117. Waldmann, TA, Dubois, S. and Tagaya, Y. (2001) Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: Implications for immunotherapy. Immunity, 14, pp. 105-110.
118. Bulfone-PauS, S., Bulanova, E. and Pohl, T. (1999) Death deflected: IL-15 inhibits TNF-alpha-mediated apoptosis in fibroblasts by TRAF2 recruitment to the IL-15Ralpha chain. FASEB J, 13, pp. 1575-1585.
119. + T-cells. Blood, 101, pp. 1024-1029.
120. + effector-memory T-cells. Int Immunol, 15, pp. 49-58.
121. + T-cells for use in adoptive immunotherapy of established tumors. Nat Med, 12, pp. 335-341.
122. Peggs, KS, Verfuerth, S. and Pizzey, A. (2003) Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet, 362, pp. 1375-1377.
123. Leen, AM, Myers, GD and Sili, U. (2006) Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med, 12, pp. 1160-1166.
124. Straathof, KC, Bollard, CM and Popat, U. (2005) Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood, 105, pp. 1898-1904.
125. Tey, SK and Brenner, MK. (2007) The continuing contribution of gene marking to cell and gene therapy. Mol Ther, 15, pp. 666-676.
126. Bonini, C., Bondanza, A. and Perna, SK (2007) The suicide gene therapy challenge: How to improve a successful gene therapy approach. Mol Ther, 15, pp. 1248-1252.
127. Schroder, AR, Shinn, P. and Chen, H. (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 110, pp. 521-529.
128. Crise, B. and Burgess, SM. (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science, 300, pp. 1749-1751.
129. Dudley, ME, Wunderlich, JR and Yang, JC (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 23, pp. 2346-2357.
130. Atkins, MB, Kunkel, L. and Sznol, M. (2000) High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am, 6, p. S11.
131. + T-cells for the treatment of patients with metastatic melanoma. J Clin Oncol, 24, pp. 5060-5069.
132. Miller, JS, Soignier, Y. and Panoskaltsis-Mortari, A. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 105, pp. 3051-3057.